Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Male

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Thrombosis Journal|December 12, 2018
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I studyDagmar Kubitza, Stefan Willmann, Michael Becka, et al.
Seminars in Thrombosis and Hemostasis|September 19, 2024
Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT TrialHope P Wilson, Maua Mosha, Alexandra Miller, et al.
Research and Practice in Thrombosis and Haemostasis|June 5, 2023
Corrigendum to 'The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study' [Research and Practice in Thrombosis and Haemostasis, 6/2, (2022) e12690]Adrian Minford, Leonardo R Brand Ao, Maha Othman, et al.
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Haematologica|January 11, 2020
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studyChristoph Male, Nadine G Andersson, Anne Rafowicz, et al.
Clinical Pharmacology and Therapeutics|June 19, 2021
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo FrameworkTjitske M van der Zanden, Miriam G Mooij, Nienke J Vet, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohortKathelijn Fischer, Manuel Carcao, Christoph Male, et al.
Journal of Thrombosis and Haemostasis : JTH|November 11, 2020
Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnessNeil A Goldenberg, Anthony Sochet, Manuela Albisetti, et al.
Journal of Thrombosis and Haemostasis : JTH|January 11, 2025
Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatmentMarisol Betensky, Manuela Albisetti, Tina Biss, et al.
Research and Practice in Thrombosis and Haemostasis|December 3, 2024
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational TrialGary M Woods, Alexandra Miller, Maua Mosha, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Thrombosis Journal|December 12, 2018
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I studyDagmar Kubitza, Stefan Willmann, Michael Becka, et al.
Seminars in Thrombosis and Hemostasis|September 19, 2024
Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT TrialHope P Wilson, Maua Mosha, Alexandra Miller, et al.
Research and Practice in Thrombosis and Haemostasis|June 5, 2023
Corrigendum to 'The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study' [Research and Practice in Thrombosis and Haemostasis, 6/2, (2022) e12690]Adrian Minford, Leonardo R Brand Ao, Maha Othman, et al.
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Haematologica|January 11, 2020
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studyChristoph Male, Nadine G Andersson, Anne Rafowicz, et al.
Clinical Pharmacology and Therapeutics|June 19, 2021
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo FrameworkTjitske M van der Zanden, Miriam G Mooij, Nienke J Vet, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohortKathelijn Fischer, Manuel Carcao, Christoph Male, et al.
Journal of Thrombosis and Haemostasis : JTH|November 11, 2020
Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnessNeil A Goldenberg, Anthony Sochet, Manuela Albisetti, et al.
Journal of Thrombosis and Haemostasis : JTH|January 11, 2025
Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatmentMarisol Betensky, Manuela Albisetti, Tina Biss, et al.
Research and Practice in Thrombosis and Haemostasis|December 3, 2024
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational TrialGary M Woods, Alexandra Miller, Maua Mosha, et al.
Pageof 14